LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
-7.46%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$699M
AUM Growth
+$699M
(-18%)
Cap. Flow
-$58.8M
Cap. Flow
% of AUM
-8.41%
Top 10 Holdings %
Top 10 Hldgs %
51.76%
Holding
52
New
12
Increased
5
Reduced
17
Closed
9
Top Buys
| 1 |
Biogen
BIIB
|
$27.8M |
| 2 |
Neurocrine Biosciences
NBIX
|
$20.2M |
| 3 |
Ascendis Pharma
ASND
|
$16.1M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$14.6M |
| 5 |
Galapagos
GLPG
|
$13.5M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$36.3M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
$20.7M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
$14.6M |
| 4 |
Fulcrum Therapeutics
FULC
|
$14.6M |
| 5 |
Ventyx Biosciences
VTYX
|
$13M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Arcutis Biotherapeutics
ARQT
$1.91B
| – | – |
-1,400,000
| Closed | -$20.7M |
|
52
AnaptysBio
ANAB
$630M
| – | – |
-250,000
| Closed | -$7.75M |
|